Search results
Results from the WOW.Com Content Network
Pomalidomide, sold under the brand names Pomalyst and Imnovid, [7] [8] is an anti-cancer medication used for the treatment of multiple myeloma and AIDS-related Kaposi sarcoma. [ 7 ] Pomalidomide was approved for medical use in the United States in February 2013, [ 10 ] and in the European Union in August 2013. [ 8 ]
Pomalidomide (3-aminothalidomide) was the second thalidomide analog to enter the clinic being more potent than both of its predecessors. [12] First reported in 2001, pomalidomide was noted to directly inhibit myeloma cell proliferation and thus inhibiting MM both on the tumor and vascular compartments. [ 13 ]
Elotuzumab is recommended through intravenous administration at 10 mg/kg each week for the first 2 cycles (each cycle is 28 days). [3] At the start of cycle 3, administer 20 mg/kg every 4 weeks, while administering the recommended dose of pomalidomide and low dose dexamethasone. [3]
Regardless, if you're interested in taking AA supps, talk to your doctor first to make sure it's safe for you to take them. Potential risks: Some negative side effects like muscle cramps, facial ...
However, safety data is limited, and there isn't enough evidence that NAD supplements are safe for pregnant people. If you have any underlying conditions or health concerns, talk to your doctor ...
When her will was read and Archerd learned his take was $1, he dug his fingers into her daughter’s shoulders so hard it nearly buckled her knees. “Accidental barbiturate overdose,” the ...
Lenalidomide is closely related to thalidomide, which is known to cause severe birth defects, so its use during pregnancy is very likely to harm the fetus. [ 8 ] Lenalidomide belongs to a class of drugs known as immunomodulatory imide drugs (IMiDs) or Cereblon E3 ligase modulators , which includes thalidomide and its analogs. [ 9 ]
What I liked about Storyworth. There’s a lot to like about Storyworth, assuming you either choose to answer the questions yourself or choose to pepper a willing participant.